Kenneth M. Peters

Safety and Efficacy of Vibegron in Men With Overactive Bladder Symptoms on Pharmacotherapy for Benign Prostatic Hyperplasia: Results From the 28-Week Open-Label COURAGE Extension Trial Completing the 52-Week Phase 3 Evaluation

David Staskin, Janet Owens‐Grillo, Elizabeth Thomas, Kenneth M. Peters et autres

Purpose: In the 24-week, phase 3 COURAGE trial, vibegron was associated with significant improvements vs placebo in all primary and key secondary efficacy end points and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH). …

us (code pays fourni par la source)

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial

Kenneth M. Peters, Janet Owens‐Grillo, Elizabeth Thomas, David Staskin et autres

OBJECTIVE: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes. METHODS: …

us (code pays fourni par la source)

UCF-10 IMPACT OF INTERNATIONAL VESICOVAGINAL FISTULA EXPERIENCE ON URPS FELLOWS

Karis Buford, Regine Sanchez, Bernadette M. M. Zwaans, Priya Padmanabhan et autres

MP11-15 THE PHASE 3 OPEN-LABEL COURAGE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF VIBEGRON IN MEN WITH OVERACTIVE BLADDER SYMPTOMS ON PHARMACOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA

David Staskin, Janet Owens‐Grillo, Elizabeth Thomas, Kenneth M. Peters et autres

Insights into the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI and post-accutane syndromes: lessons learned from a case study

Jackson Stachelek, Bernadette M. M. Zwaans, Roni M. Shtein, Kenneth M. Peters

us (code pays fourni par la source)

LBA01-19 LONG-TERM EFFICACY AND SAFETY OF URO-902 (PVAX/ HSLO ) IN WOMEN WITH OVERACTIVE BLADDER AND URGE URINARY INCONTINENCE: FINAL RESULTS OF A PHASE 2A TRIAL

Kenneth M. Peters, Ekene Enemchukwu, Susan Kalota, Kaiser J. Robertson et autres

You have accessJournal of UrologyCME1 Apr 2023LBA01-19 LONG-TERM EFFICACY AND SAFETY OF URO-902 (PVAX/HSLO) IN WOMEN WITH OVERACTIVE BLADDER AND URGE URINARY INCONTINENCE: FINAL RESULTS OF A PHASE 2A TRIAL Kenneth M. Peters, Ekene A. Enemchukwu, Susan Kalota, Kaiser Robertson, Sijian Ge, …

Incidence of New or Worsening Overactive Bladder Among Patients with a Prior SARS-CoV-2 Infection: A Cohort Study

Ly Hoang Roberts, Bernadette Zwaans, Kenneth M. Peters, Michael B. Chancellor et autres

Literature is sparse on COVID-19-associated cystitis (CAC), a novel condition comprising frequency, urgency, and nocturia after COVID-19 infection. To determine the incidence of CAC and correlation with SARS-CoV-2 antibody levels. This was a retrospective study in which urinary symptoms were scored using …

us (code pays fourni par la source)

Post orgasmic illness syndrome successfully managed with antihistamine: A case report

Andrew Shanholtzer, J. Stephens, Carl B. Lauter, Kenneth M. Peters

Post orgasmic illness syndrome (POIS) is increasingly being recognized as a debilitating cause of sexual dysfunction in males. It is often misdiagnosed due to its unfamiliarity to providers, resulting in numerous potentially unnecessary tests and treatments. Currently, there is no known single …

us (code pays fourni par la source)

298 THE INCIDENCE OF NEW OR WORSENING OAB SYMPTOMS IN PATIENTS WITH PRIOR SARS COV-2 INFECTION: A COHORT STUDY

Ly Hoang Roberts, Bernadette Zwaans, Kenneth M. Peters, Michael B. Chancellor et autres

us (code pays fourni par la source)

6 EFFICACY AND SAFETY OF A NOVEL GENE THERAPY (URO-902; PVAX/HSLO) IN FEMALE PATIENTS WITH OVERACTIVE BLADDER SYNDROME AND URGENCY URINARY INCONTINENCE: RESULTS FROM A PHASE 2A TRIAL

Kenneth M. Peters, E Enemchukwu, S Kalota, K Robertson et autres

us (code pays fourni par la source)

Transvaginal Trigger Point Injections Improve Pain Scores in Women With Pelvic Floor Hypertonicity and Pelvic Pain Conditions

Jamie Bartley, Esther Han, Priyanka Gupta, Natalie Gaines et autres

(Abstracted from Female Pelvic Med Reconstr Surg 2019;25:392–396) About 1 in 7 women in the United States has chronic pelvic pain. This condition has a negative impact on quality of life as a result of significant physical, emotional, and psychological effects.

us (code pays fourni par la source)

Reply

Kenneth M. Peters, Bradley Rosenberg, Judith Boura, Kim A. Killinger et autres

us (code pays fourni par la source)